Last Price$175.1(6.4%)
Market Cap$13.6B
P/EBITDA LTM
19.0x
5Y avg
41.9x
Medical - Devices industry
median
(1.0x)
Stock quality & Intrinsic value
6/10
0.1% undervalued
Align Technology, Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 73.0x | 31.5x | (100.8x) | 84.7x | 19.7x | (40.0x) | 15.4x | 22.1x | 17.1x | 29.8x | 21.3x | 26.6x | 29.4x | 51.4x | 33.0x | 38.8x | 99.5x | 51.2x | 20.8x | 31.2x |
Overvalued or undervalued?
Check the intrinsic value for ALGN
and see if it's the right time to invest.
Align Technology, Inc. (ALGN) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Align Technology, Inc.ALGN
18.1x
3.4%
26.0%
11.5%
Median Peer Set
24.6x
5.6%
126.3%
12.7%
Insulet CorporationPODD
47.1x
30.0%
4,364.6%
12.2%
Boston Scientific CorporationBSX
40.0x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
38.2x
11.3%
(1.4%)
14.3%
Stryker CorporationSYK
33.6x
10.2%
(5.8%)
13.2%
Edwards Lifesciences CorporationEW
25.5x
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
23.6x
(0.8%)
118.1%
(3.9%)
Abbott LaboratoriesABT
22.3x
4.6%
134.5%
31.9%
STERIS plcSTE
17.9x
3.6%
257.9%
7.4%
Medtronic plcMDT
16.4x
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
11.9x
6.5%
253.2%
13.8%
ALGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 172.8 0.0% | 207.1 19.8% | 206.4 (0.4%) | 284.3 37.8% | 304.0 6.9% | 312.3 2.7% | 387.1 23.9% | 479.7 23.9% | 560.0 16.7% | 660.2 17.9% | 761.7 15.4% | 845.5 11.0% | 1,079.9 27.7% | 1,473.4 36.4% | 1,966.5 33.5% | 2,406.8 22.4% | 2,471.9 2.7% | 3,952.6 59.9% | 3,734.6 (5.5%) | 3,862.3 3.4% |
| Cost of Goods Sold (COGS) | 57.5 | 63.8 | 64.8 | 75.0 | 78.9 | 78.8 | 83.7 | 118.5 | 143.7 | 162.1 | 183.2 | 205.4 | 264.6 | 356.5 | 518.6 | 662.9 | 708.7 | 1,017.2 | 1,100.9 | 1,155.4 |
% margin | 115.3 66.7% | 143.3 69.2% | 141.6 68.6% | 209.3 73.6% | 225.1 74.1% | 233.5 74.8% | 303.4 78.4% | 361.3 75.3% | 416.4 74.3% | 498.1 75.4% | 578.4 75.9% | 640.1 75.7% | 815.3 75.5% | 1,116.9 75.8% | 1,447.9 73.6% | 1,743.9 72.5% | 1,763.2 71.3% | 2,935.4 74.3% | 2,633.8 70.5% | 2,706.9 70.1% |
| Operating Expenses | 105.5 | 140.9 | 179.1 | 175.4 | 203.4 | 266.2 | 204.8 | 270.9 | 294.2 | 336.9 | 384.9 | 451.5 | 566.4 | 763.3 | 981.3 | 1,229.4 | 1,376.1 | 1,959.0 | 1,979.7 | 2,063.5 |
| Research & Development Expenses (R&D) | 15.8 | 18.6 | 18.5 | 25.7 | 26.2 | 22.3 | 26.0 | 37.2 | 42.9 | 44.1 | 52.8 | 61.2 | 75.7 | 97.6 | 128.9 | 157.4 | 175.3 | 250.3 | 305.3 | 346.8 |
| Selling, General & Administrative Expenses (SG&A) | 89.8 | 122.3 | 160.6 | 151.5 | 177.2 | 174.3 | 178.8 | 231.3 | 247.9 | 292.8 | 332.1 | 390.2 | 490.7 | 665.8 | 852.4 | 1,072.1 | 1,200.8 | 1,708.6 | 1,674.5 | 1,703.4 |
% margin | 9.8 5.7% | 2.4 1.2% | (37.5) (18.2%) | 33.9 11.9% | 15.5 5.1% | (34.0) (10.9%) | 102.7 26.5% | 90.4 18.8% | 85.6 15.3% | 94.2 14.3% | 193.6 25.4% | 188.6 22.3% | 248.9 23.1% | 353.6 24.0% | 466.6 23.7% | 407.5 16.9% | 293.6 11.9% | 976.4 24.7% | 642.6 17.2% | 643.3 16.7% |
| Interest Income | 0.7 | 1.9 | 3.2 | 4.2 | 3.1 | 0.6 | 0.6 | 0.6 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.6 | 12.5 | 3.1 | 3.1 | 5.4 | 17.3 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 11.2 | 0.0 | 0.0 | 0.0 | 36.0 | 5.4 | 0.0 |
| Pre-tax Income | 9.8 | 2.7 | (34.1) | 37.0 | 17.1 | (33.9) | 102.0 | 89.9 | 84.3 | 93.1 | 190.4 | 186.1 | 242.6 | 364.8 | 466.7 | 562.7 | 378.9 | 1,012.4 | 599.1 | 641.2 |
% effective tax rate | 1.0 10.2% | 1.3 48.2% | 0.8 (2.4%) | 1.2 3.3% | (62.9) (368.4%) | (2.6) 7.7% | 27.8 27.2% | 23.2 25.8% | 25.6 30.4% | 28.8 31.0% | 44.5 23.4% | 42.1 22.6% | 51.2 21.1% | 130.2 35.7% | 57.7 12.4% | 112.3 20.0% | (1,396.9) (368.6%) | 240.4 23.7% | 237.5 39.6% | 196.2 30.6% |
% margin | 8.8 5.1% | 1.4 0.7% | (35.0) (16.9%) | 35.7 12.6% | 80.0 26.3% | (31.3) (10.0%) | 74.3 19.2% | 66.7 13.9% | 58.7 10.5% | 64.3 9.7% | 145.8 19.1% | 144.0 17.0% | 189.7 17.6% | 231.4 15.7% | 400.2 20.4% | 442.8 18.4% | 1,775.9 71.8% | 772.0 19.5% | 361.6 9.7% | 445.1 11.5% |
| EPS | 0.15 | 0.02 | (0.55) | 0.53 | 1.20 | (0.45) | 0.98 | 0.86 | 0.73 | 0.80 | 1.81 | 1.80 | 2.38 | 2.89 | 5.00 | 5.57 | 22.55 | 9.78 | 4.62 | 5.82 |
| Diluted EPS | 0.14 | 0.02 | (0.55) | 0.50 | 1.18 | (0.45) | 0.95 | 0.83 | 0.71 | 0.78 | 1.77 | 1.77 | 2.33 | 2.83 | 4.92 | 5.53 | 22.41 | 9.69 | 4.61 | 5.81 |
% margin | 9.8 5.7% | 12.9 6.2% | (23.6) (11.4%) | 47.2 16.6% | 29.9 9.8% | (20.8) (6.7%) | 116.2 30.0% | 90.4 18.8% | 102.1 18.2% | 178.1 27.0% | 211.4 27.8% | 206.6 24.4% | 272.9 25.3% | 391.4 26.6% | 521.3 26.5% | 666.0 27.7% | 387.2 15.7% | 976.4 24.7% | 755.4 20.2% | 799.0 20.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Align Technology, Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 19.0x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Align Technology, Inc. have been 34.8x over the past three years, and 43.9x over the past five years.
2) Is Align Technology, Inc.'s P/EBITDA LTM Good?
As of today, Align Technology, Inc.'s P/EBITDA LTM is 19.0x, which is higher than industry median of (1.0x). It indicates that Align Technology, Inc.'s P/EBITDA LTM is Bad.